Related references
Note: Only part of the references are listed.Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics
Sravanthi Cheeti et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2021)
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Roisin M. Connolly et al.
CLINICAL CANCER RESEARCH (2020)
Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Vivek Subbiah et al.
LANCET ONCOLOGY (2020)
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction
Naoko Takebe et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G. V. Long et al.
ANNALS OF ONCOLOGY (2017)
Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma
Daniele Ouellet et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Trametinib: A novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma
Clement Chung et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2015)
Paradoxical oncogenesis: are all BRAF inhibitors equal?
Alexander M. Menzies et al.
PIGMENT CELL & MELANOMA RESEARCH (2013)
Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
Junping Jing et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Jeffrey R. Infante et al.
LANCET ONCOLOGY (2012)
Promises from Trametinib in RAF Active Tumors
Edward A. Sausville
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
Aidan G. Gilmartin et al.
CLINICAL CANCER RESEARCH (2011)
Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)
Hiroyuki Abe et al.
ACS MEDICINAL CHEMISTRY LETTERS (2011)
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
K. H. T. Paraiso et al.
BRITISH JOURNAL OF CANCER (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Identification of JTP-70902, a p15INK4b-inductive compound, as a novel MEK1/2 inhibitor
Takayuki Yamaguchi et al.
CANCER SCIENCE (2007)
Share Paper
